Policy / Regulatory

Anhui and Qinghai Provinces Update BMI Chronic Disease Drug Lists for Outpatient Reimbursement

CompanyDrug

Huadong Medicine’s Mefatinib Poised for Breakthrough Therapy Designation by CDE

CompanyDeals

VivaVision Biotech Secures Over RMB 100 Million in Series D2 Financing for Ophthalmology Pipeline Expansion

CompanyDrug

Yantai Dongcheng Pharma’s 177Lu-LNC1003 Cleared for US FDA Phase I Study

CompanyDrug

ABM Therapeutics’ ABM-168 Begins Phase I Dosing in the US for Advanced Solid Tumors

CompanyDeals

Kangrui Health Partners with West China Second University Hospital for Pediatric Care Innovation

Policy / RegulatoryR&D

China’s CDE Releases 69th Batch of Generic Chemical Reference Preparations for Public Review

CompanyDrug

Innovent Biologics’ GFH925 Earns Breakthrough Therapy Designation for KRASG12C CRC Treatment

CompanyDrug

CARsgen Therapeutics’ AB011 and Tecentriq Combo Gets NMPA Approval for Gastric Cancer Treatment

CompanyDrug

Fujian Cosunter Pharmaceutical Completes Enrollment in Phase II/III Trial for GST-HG171/Ritonavir

Company

BeiGene Reports Q1 2023 Financial Growth, Advances Pipeline with Global Expansion Plans

Policy / Regulatory

China’s Regulatory Bodies Unveil Guidelines to Strengthen Supervision of Medical Aesthetic Industry